Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergy and antagonism between azacitidine and FLT3 inhibitors.

Computers in biology and medicine - 1 Feb 2024

Yang Jingmei, Friedman Ran

Abstract excerpt

Synergetic interactions between drugs can make a drug combination more effective. Alternatively, they may allow to use lower concentrations and thus avoid toxicities or side effects that not only cause discomfort but might also reduce the overall survival. Here, we studied whether synergy exists between agents that are used for treatment of acute myeloid leukaemia (AML). Azacitidine is a demethylation agent that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Aniline Compounds
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzothiazoles

Share to fms-Like Tyrosine Kinase 3

Share to Phenylurea Compounds

Share to Pyrazines

Share to Pyrimidines

Source

Identifiers

PMID: 38199214
DOI: 10.1016/j.compbiomed.2023.107889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Synergy and antagonism between azacitidine and FLT3 inhibitors.PMID 38199214Read ↗

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read ↗

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read ↗

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read ↗

Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3mut acute myeloid leukemia.Semantic proximity Read ↗

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.Semantic proximity Read ↗

Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.Semantic proximity Read ↗

Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.Semantic proximity Read ↗

Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.Semantic proximity Read ↗

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.Semantic proximity Read ↗

Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.